The interim results demonstrate that the treatment has been well tolerated to date, with eight of 16 evaluable patients experiencing stable disease for periods ranging from two to more than 10, 28-day cycles.
As previously announced by Oncolytics, the third patient treated in the study was demonstrated to have stable disease by Recist criteria for more than six months as measured by CT scan. A Pet scan taken at the same time showed that any residual mass was metabolically inert.
Monica Mita, principal investigator of the study said: “Patients have tolerated the treatment well and seem to have disease control up to several months, which is encouraging for patients with advanced refractory sarcoma.”